GlassScriptPhysician profile
Laura D Mccurdy
NPI 1336309491
$3,117.41
in general payments reported to CMS, 2019-2025
32 companies · $658 in 2025
The $658 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $82.02 · 2021: $367 · 2022: $786 · 2023: $295 · 2024: $258 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $447.99 | 2022 | |
| Abbvie INC. | $357.60 | 2019-2022 | |
| Hologic Sales and Service, LLC | $278.53 | 2019-2025 | Acessa Provu System, Coolseal Generator, Omni Hysteroscope |
| Sumitomo Pharma America, INC. | $216.23 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $194.29 | 2019-2025 | Veozah, Myrbetriq |
| Lsi Solutions INC | $162.44 | 2025 | Fornisee |
| Exeltis, USA INC. | $156.50 | 2019-2025 | Slynd |
| Coopersurgical, INC. | $147.86 | 2019-2023 | Paragard T 380a, Mara Console, Endosee |
| Therapeuticsmd, INC. | $136.58 | 2019-2022 | |
| Pfizer INC. | $105.53 | 2019-2021 | |
| Organon LLC | $91.13 | 2022-2025 | Nexplanon |
| Agile Therapeutics, INC. | $82.41 | 2021-2023 | Twirla |
| Kvk-Tech, INC. | $81.11 | 2019-2020 | |
| Medtronic, INC. | $75.88 | 2024-2025 | Interstim, Altaviva |
| Coloplast Corp | $63.86 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $56.58 | 2021-2025 | |
| Avion Pharmaceuticals | $48.76 | 2019-2021 | |
| Evofem Biosciences, INC. | $45.91 | 2021 | |
| Lupin INC. | $38.44 | 2019 | |
| Millicent US INC | $37.64 | 2024 | Femring, Intrarosa |
| Bayer Healthcare Pharmaceuticals INC. | $36.22 | 2019-2023 | |
| Exact Sciences Corporation | $34.27 | 2024 | Cologuard Collection Kit |
| Vivus LLC | $32.46 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $31.86 | 2019 | |
| Amgen INC. | $28.47 | 2019 | |
| Allergan, INC. | $24.87 | 2019-2020 | |
| Axonics, INC. | $24.77 | 2024 | Axonics |
| Duchesnay USA Incorporated | $24.27 | 2019 | |
| Biogen, INC. | $24.08 | 2025 | Zurzuvae |
| Boston Scientific Corporation | $19.15 | 2025 | Axonics |
| Ascend Therapeutics US, LLC | $11.72 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Mccurdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.